NEW YORK, Sept. 2, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, announced encouraging preclinical results for its precision antisense candidate HT-KIT, demonstrating rapid anti-tumor efficacy, a clean safety profile, and GLP-validated bioanalytical data that surpassed internationally recognized regulatory standards. These results mark a significant step forward in the development of targeted therapies for KIT-driven cancers such as gastrointestinal stromal tumors (GIST) and systemic mastocytosis.
Science Significance
HT-KIT works by silencing mutant KIT mRNA, the oncogenic driver behind multiple aggressive cancers. Preclinical models showed tumor cell death within 24 hours of treatment, with statistically significant tumor shrinkage observed by day 8. Importantly, multi-dose studies reported no off-target toxicity across critical organs, reinforcing the therapeutic’s clean safety profile.
The candidate achieved over 80% knockdown of KIT expression in vitro, highlighting its potential to overcome resistance to standard tyrosine kinase inhibitors. Stability tests further demonstrated that HT-KIT remained intact in serum for 37 days at -80°C, exceeding validated stability benchmarks.
Regulatory Significance
The GLP-compliant study conducted by Altasciences Company, Inc. validated HT-KIT against FDA, EMA, and OECD regulatory criteria. Results showed 90.5% reproducibility in Incurred Sample Reanalysis (ISR), well above the 66.7% regulatory minimum. No deviations from protocols or SOPs were reported, establishing strong confidence in both the integrity and reliability of the data.
Advertisement
Such compliance strengthens HT-KIT’s case for an upcoming Investigational New Drug (IND) application and first-in-human clinical trials.
Business Significance
For Hoth Therapeutics, these findings support its strategy of advancing precision antisense oncology therapies in high-need indications. Success in this domain would not only diversify its pipeline but also position the company competitively in the oncology market, where targeted therapies command strong demand and premium valuations.
As CEO Robb Knie stated, “These results combine a rare and powerful story — tumor kill within 24 hours, clean safety across all systems, and GLP-validated reproducibility beyond regulatory standards. We believe HT-KIT has the potential to transform outcomes in KIT-driven cancers.”
Patients’ Significance
If validated in clinical trials, HT-KIT could offer patients with GIST, systemic mastocytosis, and resistant leukemias a new therapeutic option with faster onset, fewer systemic side effects, and improved durability of response. This holds particular importance for patients whose cancers no longer respond to current standard-of-care therapies.
Policy Significance
The successful progression of HT-KIT reflects the FDA’s and EMA’s policy emphasis on encouraging generic competition and innovative therapies in oncology. By exceeding regulatory thresholds, Hoth Therapeutics aligns with global health policy goals of accelerating access to safe, effective, and affordable cancer treatments.
Transaction Highlights
Rapid Efficacy: Significant tumor cell death observed within 24 hours in preclinical GIST and mastocytosis models.
High Target Knockdown: Achieved 80% suppression of KIT expression in vitro.
Safety Confirmed: No off-target toxicity across critical organs in multi-dose studies.
Regulatory Compliance: GLP study validated under FDA, EMA, and OECD standards, surpassing ISR reproducibility benchmarks.
Extended Stability: Maintained integrity in serum for 37 days, exceeding validated timelines.
Next Steps: Data to be integrated into a GLP toxicology package as the company prepares for IND submission.
Source: Hoth Therapeutics Press Release
